• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Shivom Partners With Lifebit To Power AI-Analysis of DNA Data For Clinical Trials

by Jasmine Pennic 12/18/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print
 Shivom, the blockchain genomics platform that is powering personalized healthcare, has partnered with Lifebit, the AI-powered DNA-analysis firm, to give users unprecedented reporting capabilities for DNA data analysis.
 
The partnership will mean that immediate Genome Wide Association Study (GWAS) analysis is possible, with no specialist knowledge or in-house data scientist required. It also means that users can access a library of pipelines (ready-built software that is used for analysis) and an AI-powered toolkit for analyzing the data in a way that is far more scalable than other solutions. 
 
Another aspect that makes the Shivom platform superior to other genomics platforms is that it will give pharmaceutical organizations and life science users the ability to access real-time analysis whenever they need it with no waiting time, no application process for accessing the data and deadlines or cut off dates that restrict their access.
 
“Through this partnership with Lifebit, we are providing enterprise users with the tools they need to find the right patients for their clinical trials more easily and more accurately than is possible through other solutions. Not only that, it brings AI into GWAS analysis in a way that hasn’t been seen before,” said Dr. Axel Schumacher, Co-Founder and Chief Scientific of Shivom.
 
The use of genomics platforms to improve rare disease treatment has increased in recent months, with 23andMe partnering with GlaxoSmithKline to develop drugs for Parkinson’s. However, the Shivom Lifebit partnership demonstrates a major leap forward in this area because it adds AI and Machine Learning capabilities to the identification of potential patients.
 
To do this, users will be able to access a library of pipelines within the Shivom platform. These include preset Shivom pipelines, those created through open source software and any that an enterprise chooses to develop using Github and DOCKER services.
 
“Our partnership with Shivom will allow us to combine unique datasets with a level of analysis automation and insight generation that has never been seen before on a genomics platform,” said Dr. Maria Chatzou, co-founder and CEO of Lifebit. “In this way, scientists and doctors will be able to get all the benefits of this rich database without the need to rely on a data scientist for help. On the other hand, still ensuring that the individuals that have provided data to Shivom are given a level of security and control only a state-of-art blockchain technology can offer.”
 
The partnership with Lifebit comes with the Shivom platform having already been released in alpha. The full launch of the platform is expected in Q1 2019.
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Blockchain Startups, Blockchain Technology, Clinical Trials, Healthcare Blockchain

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Interview

Reach7 Diabetes Studios Founder Chun Yong on Reimagining Chronic Care with a Concierge Medical Model

Most-Read

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Bayer Exits Radiology AI Market, Discontinuing Calantic and Blackford

Oracle Health Launches AI Center of Excellence for Healthcare

Oracle Health Launches AI Center of Excellence for Healthcare

Particle Health Addresses Integration to Epic Data Despite Dispute

US Court Allows Particle’s Antitrust Claims Against Epic to Proceed

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Preparing for the ‘Big Beautiful Bill’: How Digitization Can Streamline Medicaid Eligibility & Social Care Delivery

Evernorth Health Services Invests $3.5B in Shields Health Solutions

Evernorth Health Services Invests $3.5B in Shields Health Solutions

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

KLAS Report: Oracle Health Faces Customer Losses and Declining Satisfaction

Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

M&A:Tempus AI Acquires Digital Pathology Leader Paige for $81.25M

Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

Femtech: Mira Launches Ultra4™, the First At-Home Hormone Monitor with Lab-Quality Insights

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

How Healthcare CIOs Can Solve the Unstructured Data Crisis and Reduce Storage Costs

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |